When Sex Starts Feeling Different: The Tissue Changes of Perimenopause Your Doctor Calls Normal

"It's not painful exactly. Just... different. Drier. More sensitive in a way that doesn't feel good. And honestly, it's starting to affect whether I even want to try."

I hear some version of this every week. And almost every time, the woman telling me has already been to a doctor who looked at her exam and said something like, "Everything looks fine." Or handed her a sample of lubricant and moved on.

A normal-looking exam does not mean nothing is wrong. And lubricant, while useful, does not treat what is actually happening to your tissue. What you are noticing is real, it has a name, it has a physiological explanation, and it is treatable.

What Is Actually Happening

The tissue changes that affect the vagina, vulva, and bladder during perimenopause and menopause have a clinical name: genitourinary syndrome of menopause, or GSM. It used to be called vaginal atrophy, but that term undersells the scope of what happens and frankly, it sounds like something you have to simply accept.

GSM is driven by the decline of estrogen. Estrogen is not just a reproductive hormone. It is the primary reason vaginal tissue stays thick, elastic, and well-lubricated. When estrogen levels drop, which happens gradually through perimenopause and more sharply after the final menstrual period, that tissue begins to change at a cellular level.

Specifically:

• The vaginal lining thins and loses its layered structure.
• Collagen and elastin in the tissue decrease, reducing elasticity.
• Natural lubrication decreases because the cells responsible for it are estrogen-dependent.
• The pH of the vaginal environment shifts, making tissue more vulnerable to irritation and infection.
• Blood flow to the area decreases, which affects sensation and arousal response.
• The vestibule (the tissue at the vaginal opening) can become particularly sensitive and reactive.

This is not a cosmetic issue. It is not a minor inconvenience. It is a progressive physiological change that gets worse over time without treatment. And unlike hot flashes, which often improve on their own, GSM does not resolve without intervention.

Why Your Labs Can Look "Normal" While You Feel Anything But

Here is where the dismissal often happens. You go in, describe what you are experiencing, and your provider pulls up a blood test showing estrogen levels that look acceptable, or tells you your exam appears normal. And so you leave without treatment.

The problem is that serum estrogen levels, meaning the estrogen circulating in your blood, do not reliably predict what is happening in vaginal tissue. The tissue in your vulva and vagina is exquisitely sensitive to local estrogen. A systemic level that looks unremarkable on paper can still be insufficient to maintain tissue health in that specific environment.

Labs do not measure your experience. I treat the person in front of me, not a number on a page.

A clinical assessment of GSM is based on symptoms and tissue findings, not on serum hormone levels alone. When a provider relies only on bloodwork to tell you whether you have a problem, they are using the wrong tool.

What Lubricant and Moisturizer Can and Cannot Do

Lubricants and vaginal moisturizers are not nothing. They have a real role in managing day-to-day comfort and making sex more comfortable in the short term. I recommend them as part of care.

But they do not restore tissue. They do not rebuild the cellular layers that estrogen loss has thinned. They do not improve blood flow, restore elasticity, or shift vaginal pH back toward a healthier range. They manage symptoms in the moment. They do not treat the underlying change.

Telling a woman with GSM to use lubricant and calling it done is like telling someone with a thyroid condition to drink more water and calling it done. It addresses a surface-level symptom while leaving the physiology unaddressed.

The Treatment That Works, and Why Doctors Are Still Reluctant to Offer It

Local vaginal estrogen is the evidence-based, first-line treatment for GSM. It comes in several forms: a low-dose cream, a vaginal ring, or small suppositories called vaginal inserts. There is also a newer non-estrogen prescription option called ospemifene (an oral pill) and a DHEA-based vaginal insert called prasterone, which the body converts locally to both estrogen and testosterone.

These treatments work because they deliver estrogen (or a hormone precursor) directly to the tissue that needs it, restoring thickness, elasticity, lubrication, and pH over time. Most women notice meaningful improvement within eight to twelve weeks, with continued improvement over several months.

So why are so many women still not offered this treatment?

The short answer is a misapplication of old data. The Women's Health Initiative study, published in 2002, raised concerns about systemic hormone therapy (oral estrogen taken in high doses). Those concerns led to a widespread overcorrection in which many providers became reluctant to prescribe any form of estrogen to any woman, regardless of context.

Local vaginal estrogen is not the same as systemic hormone therapy. The doses are much lower, absorption into the bloodstream is minimal, and the safety profile is well-established. Major medical organizations, including the Menopause Society (formerly NAMS) and the American College of Obstetricians and Gynecologists, endorse local vaginal estrogen as safe and appropriate for most women, including most women with a history of breast cancer, when used in low doses.

Refusing to prescribe local estrogen based on outdated fears is not conservative medicine. It is a failure to offer a woman the standard of care.

What Else May Be Contributing

GSM does not always act alone. In perimenopause, the tissue changes often overlap with other shifts that affect sexual comfort and response:

• Pelvic floor changes: Declining estrogen affects pelvic floor muscle tone and function. Some women develop increased pelvic floor tension or hypertonicity, which makes penetration painful regardless of lubrication.
• Reduced arousal response: Decreased blood flow to the genitals means it takes longer to become aroused and produce natural lubrication. This is not a libido problem. It is a vascular and tissue response.
• Vestibulodynia: Some women develop localized sensitivity at the vaginal opening that goes beyond dryness. This requires a targeted evaluation, not just a lubricant recommendation.
• Testosterone decline: Testosterone, which drops steadily through the perimenopausal years, plays a role in genital sensation and arousal. Its decline is often underrecognized in clinical practice.
• Sleep disruption and cortisol: Poor sleep and chronic stress raise cortisol, which suppresses reproductive hormones and affects tissue quality. Women who are not sleeping are often dealing with layered hormonal effects that compound GSM.

A complete assessment looks at all of these. Not just the symptom in isolation.

You Do Not Have to Accept This as the Price of Getting Older

Women have been told, for generations, that changes in their sexual health are just part of aging. That dryness, discomfort, and lost pleasure are the expected trade-offs of midlife. That if it is not severe enough to make them cry, it probably does not warrant treatment.

None of that is true.

GSM is one of the most consistently undertreated conditions in women's medicine. It affects an estimated 50 to 80 percent of postmenopausal women, and the majority of them are either not offered treatment or do not know treatment is available. That is not a gap in patient demand. That is a gap in clinical care.

Sex that feels uncomfortable, dull, or like something to be gotten through is not a fact of midlife. It is a signal that your tissue needs support. And that support exists.

What Care Should Look Like

When I evaluate a patient for GSM, I am doing more than handing her a prescription. I am taking a full history of when symptoms started, how they have changed, what she has already tried, and what her goals are. I am looking at her pelvic floor, assessing tissue quality directly, and thinking about whether local estrogen alone is enough or whether other factors need to be addressed alongside it.

I am also asking about her overall hormonal picture: where she is in the perimenopause transition, whether systemic hormone therapy is something she has considered or is appropriate for her, and whether testosterone is worth discussing given her symptoms.

And I am listening. Not just to what she can articulate cleanly, but to what she reaches for when she says, "It just feels different."

That is information. I believe her. Full stop.

These changes are common. They are absolutely treatable. You do not have to white-knuckle your way through a version of intimacy that no longer feels like yours.

Pleasure, vitality, and feeling like yourself in your own body are not luxuries. They are what you deserve from your healthcare.

If you are ready for a real evaluation and a care plan that takes your experience seriously, I invite you to apply for membership at Sky Women's Health. This is what we do.

Warmly,

Dr. Carolyn Moyers

Sky Women's Health

Frequently Asked Questions

Is vaginal estrogen safe if I have a history of breast cancer?

This is one of the most common questions I hear, and it deserves a direct answer. Low-dose local vaginal estrogen has minimal systemic absorption, meaning very little enters your bloodstream. Major oncology and menopause organizations, including the Menopause Society and the American College of Obstetricians and Gynecologists, consider low-dose vaginal estrogen appropriate for most breast cancer survivors, particularly those whose cancer was hormone receptor-negative or who are at lower risk. If you have a hormone receptor-positive cancer history, the conversation is more nuanced, but non-estrogen options like prasterone (DHEA) or ospemifene may be appropriate alternatives. This is a decision to make with a clinician who knows your specific history, not one to skip because of a blanket fear.

My doctor said my exam looked normal. Does that mean I do not have GSM?

Not necessarily. Early GSM can be present without obvious visible changes on a routine exam. More importantly, your symptoms are not explained away by a normal-looking exam. GSM is a clinical diagnosis that depends on your experience of your symptoms, not just on what your provider sees. Serum estrogen levels also do not reliably predict whether your vaginal tissue is getting adequate estrogen support. If you are experiencing dryness, discomfort with sex, increased sensitivity, or changes in sensation, those symptoms deserve evaluation and treatment regardless of what a quick exam shows.

I am still having periods. Can I really have vaginal dryness from estrogen changes?

Yes. Perimenopause can begin years before your last period, and estrogen levels during this transition are erratic rather than steadily low. Even while you are still cycling, your tissue can be experiencing the effects of estrogen fluctuation. Vaginal dryness, increased sensitivity, and changes in sexual comfort are common in perimenopause, not just after menopause. You do not have to wait until your periods stop to seek evaluation or treatment.

Will lubricant not be enough? Do I really need a prescription?

Lubricant helps in the moment and is a reasonable part of managing symptoms. But it does not restore tissue. It does not rebuild the cellular layers that have thinned, improve blood flow, restore elasticity, or correct the pH shift that makes tissue more vulnerable to irritation and infection. If your symptoms are mild and a good-quality lubricant (ideally silicone-based for intercourse, or water-based with a matched pH for everyday use) is keeping you comfortable, that may be sufficient for now. But if you are noticing persistent dryness, discomfort, chafing, or changes in sensation, lubricant alone is not a treatment plan. It is a workaround.

How long does it take for vaginal estrogen to work?

Most women notice some improvement within four to eight weeks, with more significant tissue restoration by twelve weeks of consistent use. Estrogen-dependent tissue changes did not happen overnight, and they do not reverse overnight either. The important thing to know is that improvement continues over time, and the treatment works best when it is maintained rather than used intermittently. For most women, local vaginal estrogen is a long-term part of their care plan, not a short course to get through symptoms and then stop.